Altuviiio market report sees long-acting hemophilia therapies driving growth

The Business Research Company says the global Altuviiio market is expanding as hemophilia A treatment shifts toward longer-acting therapies and better prophylaxis. North America led the market in 2025, while Europe is expected to grow fastest through 2035.

Why it matters: - Altuviiio sits in a hemophilia A market that is being reshaped by demand for fewer injections, better adherence and longer-lasting protection against bleeding. - The report ties market growth to rising hemophilia prevalence, which increases the need for advanced clotting-factor therapies. - The findings matter for drug makers, treatment centers and payers tracking how extended half-life therapies could change hemophilia care.

What happened: - The Business Research Company released its Altuviiio Market Report 2026, covering market size, trends and global forecast through 2035. - The report says Altuviiio, the brand name for efanesoctocog alfa, is a therapy for hemophilia A caused by clotting factor VIII deficiency. - The report frames the market around a growing shift toward innovative therapies and patient-centered treatment models.

The details: - Historical market growth was supported by continued reliance on conventional factor VIII therapies. - Frequent bleeding episodes, the need for regular infusions and early use of recombinant factors helped expand demand. - More hemophilia treatment centers also supported market growth. - Future growth is expected to be driven by demand for long-acting therapies. - Broader adoption of prophylaxis guidelines is expected to support that growth. - Increased treatment among pediatric patients is another expected driver. - Advances in clotting factor engineering are likely to improve the market outlook. - Improved reimbursement policies are also expected to help adoption. - The forecast period is shaped by movement toward extended half-life factor therapies. - Those therapies can reduce the number of injections needed. - The report says reduced injection burden can improve adherence and quality of life. - Acceptance of prophylactic treatment is expanding. - Demand is also rising for more advanced recombinant factors. - The report says Altuviiio aims to provide prolonged protection against bleeding episodes while reducing dose frequency compared with traditional factor VIII therapies. - Rising hemophilia prevalence is a major market driver. - Improved diagnostics and treatment advances have increased detection rates and patient longevity, which lifts demand for effective therapies. - National Blood Authority data in Australia showed 2,788 people living with hereditary hemophilia A in 2023-2024, up from 2,681 a year earlier. - That increase underscores the expanding patient pool for advanced treatment options. - North America held the largest share of the global Altuviiio market in 2025. - Europe is expected to post the fastest growth during the forecast period. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report offers a free sample and a full version via the sample request page and the full market report.

Between the lines: - The report points to a market moving away from frequent infusion-based care toward more convenient prophylactic treatment. - That shift suggests competition will hinge on dosing convenience, reimbursement and pediatric uptake as much as on clinical efficacy. - The regional split implies North America remains the commercial center, but Europe may become a key growth engine.

What's next: - Adoption of extended half-life therapies will likely remain the main indicator to watch in the Altuviiio category. - Payer policy, pediatric treatment patterns and factor-engineering advances should continue to shape demand through 2035. - The company says interested readers can contact Saumya Sahay for more information at +1 310-496-7795, +44 7882 955267, +91 8897263534 or marketing@tbrc.info. - The Business Research Company also directs readers to its website, LinkedIn page, LinkedIn profile, Facebook page and X account.

The bottom line: - Altuviiio is positioned in a hemophilia market where longer-acting treatments, wider prophylaxis use and rising patient numbers are expected to drive the next phase of growth.